Announcement on Company Products Being Selected for the 12th National Centralized Drug Procurement

Zhejiang Xianju Pharmaceutical Co., Ltd.·August 3, 2026·2 pages

✨ AI Summary

Zhejiang Xianju Pharmaceutical announced its products were selected for the 12th national centralized drug procurement. This selection is expected to impact future sales and revenue, with specific figures provided for projected sales of selected products in 2025 and 2026. The company acknowledges uncertainties regarding procurement agreements and future performance.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

[Document Number: 002332]

[Certificate Number: Xianju Pharmaceutical]

[Approval Number: 2026-042]

Announcement on Zhejiang Xianju Pharmaceutical Co., Ltd. Products Being Selected for the 12th National Centralized Drug Procurement

The Board of Directors and all members of the Supervisory Board guarantee the authenticity, accuracy, and completeness of the information disclosed herein, and assume no joint and several liability for any false representations, misleading statements or material omissions.

Zhejiang Xianju Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") will participate in the 12th batch of national centralized drug procurement organized by the National Healthcare Security Administration's Centralized Drug Procurement Office. The Company's products selected for this round of centralized procurement are as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.